CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-06-05 | HAYDEN DONALD J JR Director | Exercise or conversion · Stock Option (Right to Buy) | −14,900 | 189,100 | ||
| 2018-06-01 | HAYDEN DONALD J JR Director | Exercise or conversion | +100 | $0.85 | $85 | 100 |
| 2018-06-01 | HAYDEN DONALD J JR Director | Sale | −100 | $55.00 | $6K | 0 |
| 2018-06-01 | HAYDEN DONALD J JR Director | Exercise or conversion · Stock Option (Right to Buy) | −100 | 204,000 | ||
| 2018-05-25 | KARABELAS ARGERIS N Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | Tasse Daniel Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | STUMP DAVID C Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | HAYDEN DONALD J JR Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | Fox Allan M. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | BESHAR LUKE M Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | Abdun-Nabi Daniel Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2018-05-25 | Glucksmann Alexandra Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2018-05-21 | Mills Kenneth T. President and CEO | Sale | −6,799 | $46.56 | $317K | 211,731 |
| 2018-05-21 | Mills Kenneth T. President and CEO | Sale | −1,800 | $47.88 | $86K | 209,931 |
| 2018-05-21 | Mills Kenneth T. President and CEO | Sale | −1,401 | $48.39 | $68K | 208,530 |
| 2018-05-15 | Vasista Vittal Chief Financial Officer | Sale | −1,100 | $49.21 | $54K | 151,183 |
| 2018-05-15 | Vasista Vittal Chief Financial Officer | Sale | −3,945 | $49.93 | $197K | 147,238 |
| 2018-05-15 | Vasista Vittal Chief Financial Officer | Sale | −2,455 | $50.76 | $125K | 144,783 |
| 2018-05-15 | HAYDEN DONALD J JR Director | Exercise or conversion | +9,847 | $0.85 | $8K | 9,847 |
| 2018-05-15 | HAYDEN DONALD J JR Director | Sale | −9,847 | $50.06 | $493K | 0 |
Page 41 of 43 · 852 trades